In the adjuvant treatment of breast cancer, the classes of systemic therapies have evolved from chemotherapy, hormonal therapy and anti-HER2 targeted therapy to include novel targeted therapies including PARPis. The gene discussed is ERBB2; the disease is breast carcinoma.